BioMS Medical Corp.
TSX : MS

BioMS Medical Corp.

November 08, 2007 08:00 ET

BioMS Medical Corp.-Webcast Alert: Biotech/Pharma/Healthcare On-line Forum

EDMONTON, ALBERTA--(Marketwire - Nov. 8, 2007) - BioMS Medical Corp. (TSX:MS) announces the following Webcast:



What: Biotech/Pharma/Healthcare On-line Forum

When: November 13, 2007 @ 10:30 AM Eastern

Where: www.investorcalendar.com/ClientPage.asp?ID=122564

How: Live over the Internet - Simply log on to the web at the address
above.


If you are unable to participate during the live webcast, the call will be available for replay at www.investorcalendar.com/ClientPage.asp?ID=122564 or http://www.investorcalendar.com/

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies with emphasis on the treatment of multiple sclerosis (MS). BioMS Medical has obtained an exclusive worldwide license to a proprietary technology developed at the MS Patient Care and Research Clinic at the University of Alberta for the treatment of MS. The technology, MBP8298, is a synthetic myelin basic protein peptide comprised of 17 amino acids which is intravenously injected (every six months) into MS patients as a therapeutic treatment. MBP8298 is currently being evaluated in two pivotal phase III clinical trials for secondary progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. MBP8298 is also being evaluated for relapsing remitting MS patients in a Phase II trial in Europe entitled MINDSET-01.

Contact Information